Oncolytic Virus CDMO Services Market to Reach USD 1734.41 Million, at 15.25% CAGR by 2035
The global oncolytic virus CDMO services market size is valued at USD 419.51 million in 2025 and is predicted to hit around USD 1734.41 million by 2035, rising at a 15.25% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.
Ottawa, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The global oncolytic virus CDMO services market size is calculated at USD 483.49 million in 2026 and is expected to reach around USD 1734.41 million by 2035, growing at a CAGR of 15.25% for the forecasted period.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/6341
Key Takeaways
- North America was dominant in the market share 40% in 2024.
- Asia-Pacific is expected to grow at a rapid CAGR during 2025-2034.
- By service type, the upstream manufacturing segment held the largest revenue share of the market in 2024.
- By service type, the downstream manufacturing segment is expected to be the fastest-growing during the forecast period.
- By virus type, the adenovirus segment registered dominance in the market in 2024.
- By virus type, the herpes simplex virus (HSV) segment is expected to witness rapid expansion during 2025-2034.
- By therapeutic area, the melanoma segment led the oncolytic virus CDMO services market in 2024.
- By therapeutic area, the glioblastoma segment is expected to grow rapidly in the coming years.
- By end-user, the pharmaceutical companies segment dominated the market in 2024.
- By end-user, the biotechnology companies segment is expected to be the fastest-growing in the predicted timeframe.
Emphasis on Combination Therapies: How are the Latest Efforts Revolutionizing Oncolytic Viruses?
Day by day, the globe is facing a huge burden of cancer instances, especially among the ageing population, for which researchers are fostering the production of oncolytic viruses for cancer therapy with the major contribution of expertise and facilities. The oncolytic virus CDMO services market is further propelled by ongoing technological breakthroughs in delivery systems, the growth of combination therapies with immune checkpoint inhibitors, and supportive regulatory frameworks. Nowadays, scientists are accelerating the development of viruses with targeted therapies, and combination therapies, such as onCARlytics (CF33-CD19), can be used in conjunction with CAR-T cells and other immunotherapies to target solid tumours.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
What are the Key Drivers Involved in the Market Expansion?
In this era, numerous pharmaceutical and biotech companies are greatly outsourcing the complex manufacturing of oncolytic viruses to specialized CDMOs to foster research and development and to handle expenditures more efficiently. Whereas, persistent major investments and funding in the oncolytic virus area are further assisting progression and demand for relevant CDMO services.
What are the Trends in the Oncolytic Virus CDMO Services Market?
- In November 2025, Matica Biotechnology, Inc., a major viral vector CDMO specializing in advanced therapies, partnered with Calidi Biotherapeutics, Inc. to boost Calidi's project toward IND.
- In May 2025, TILT Biotherapeutics, a biotechnology company, secured $25.6 million in Series B funding to expand the advancement of their Phase 2 clinical trial for TILT-123, targeting platinum-resistant epithelial ovarian cancer.
- In November 2025, Genezen, a vital viral vector Contract Development and Manufacturing Organization (CDMO), and Humane Genomics, a biotechnology company developing oncolytic viral therapies, collaborated for process transfer and cGMP manufacturing of HGI627.
What is the Emerging Challenge in the Oncolytic Virus CDMO Services Market?
The maintenance of quality, the difficulties of production during the scaling up of these biological products, as well as navigating stringent regulatory compliance, and the increased spending on development and manufacturing, are creating hurdles in the market.
Regional Analysis
What Made North America Dominant in the Market in 2024?
In 2024, North America captured the biggest revenue share by 40% of the market. In this region, especially in the US and Canada, a rise in the number of clinical trials for oncolytic virus therapies is increasingly demanding particular production assistance for the testing of the safety and efficiency of novel treatments. Recently, the California-based Calidi Biotherapeutics received the FDA fast track designation for its oncolytic virus candidate, CLD-201, for use in combination therapy. Whereas, KaliVir Immunotherapeutics launched a novel state-of-the-art GMP cleanroom facility to produce its pipeline of oncolytic viruses and successfully implemented an inaugural manufacturing run for its main clinical candidate, VET3-TGI.
Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting
How did the Asia Pacific Grow Notably in the Market in 2024?
During 2025-2034, the Asia Pacific is anticipated to expand rapidly in the oncolytic virus CDMO services market. Ongoing developments in treatments and clinical trials are fostering the overall growth of the market, such as in March 2025, when Zhejiang University developed VG161, a modified virus for expressing four immune-boosting cytokines. This has shown promising results in the inhibition of tumor growth and reversing immunotherapy resistance. Moreover, Binhui Biotechnology engineered OH2, an oncolytic virus therapy to treat melanomas.
Oncolytic Virus CDMO Services Market: Companies Overview
| Company | Headquarters | Key Offering |
| Catalent Inc. (2007) | Tampa, Florida, at 101 East Kennedy Boulevard. | This mainly facilitates expertise in live virus and viral-like particle (VLP) manufacturing, using advanced technologies, including iCELLis® fixed-bed bioreactors. |
| Lonza Group (1897) | Basel, Switzerland, particularly at Muenchensteinerstrasse 38. | This explores process development, cGMP manufacturing, and regulatory support, with specific capabilities in viral vector production, improvements, and analytical testing. |
| WuXi AppTec (2000) | Shanghai, China. | A vital leader offers a full spectrum of support for oncolytic virus development through its WuXi Biology and WuXi ATU (AppTec Tianjin) divisions. |
Segmental Insights
By Service Type Analysis
The upstream manufacturing segment registered dominance in the market in 2024. The expanding cell and gene therapy sector, with substantial advances in single-use bioreactors, enhanced cell culture techniques, and improved transfection solutions, is fueling the upstream manufacturing. Current notable efforts are the rise of scalable suspension cell cultures, the use of serum-free/chemically defined media, and the development of viruses to achieve increased production outcomes and accelerated tumor selectivity/efficacy.
On the other hand, the downstream manufacturing segment will expand rapidly. The emergence of stricter regulatory guidelines that utilise strong downstream processes with deeper documentation for a feasible transition from development to commercial manufacturing, and for ensuring product quality and safety, is driving the market progression. Alongside, leaders are stepping into scalable, robust, and GMP-compliant processes, often using membrane chromatography and tangential flow filtration (TFF) to substitute traditional methods, such as ultracentrifugation, and using specific companies that offer these contract services.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
By Virus Type Analysis
Why did the Adenovirus Segment Dominate the Market in 2024?
In 2024, the adenovirus segment captured a major share of the oncolytic virus CDMO services market. This era is leveraging the expansion of capabilities for late-stage and commercial manufacturing, advanced viral vector designs, and the use of platforms that offer faster communication and problem-solving for complex projects. Recently, Vibalogics explored private equity investment, while others like Batavia Biosciences escalated collaborations to increase timelines for clients evolving novel oncolytic adenoviruses.
However, the herpes simplex virus (HSV) segment is estimated to expand fastest. One of the unique advantages of this virus type is that it can penetrate the blood-brain barrier for central nervous system tumors. These days, players are putting effort into developing second-generation oHSVs with accelerated tumor selectivity, replication effectiveness, and immunogenicity, often by arming them with therapeutic transgenes.
By Therapeutic Area Analysis
How did the Melanoma Segment Lead the Market in 2024?
The melanoma segment held a dominant share of the oncolytic virus CDMO services market in 2024. A significant driver is the rising clinical success and regulatory approvals of oncolytic viruses, especially for melanoma, which is impacting the overall manufacturing. The latest developments include more efficacious clinical trials for viruses, such as coxsackievirus and adenovirus, often as combination therapies with immune checkpoint inhibitors (ICIs) for patients who are refractory to current treatments.
Moreover, the glioblastoma segment is predicted to register the fastest growth. Oncolytic viruses are considered immunotherapy, which has the ability to alter the highly immunosuppressive GBM tumor microenvironment into an immune-active state. Prominent efforts by researchers in the exploration of solutions to load viruses into carrier cells, like human neural progenitor cells (hPSCs), to assist them in penetrating the BBB and resisting systemic immunity, as executed with the oncolytic virus CF17.
By End-user Analysis
Which End-user Dominated the Oncolytic Virus CDMO Services Market in 2024?
In 2024, the pharmaceutical companies segment held the biggest share of the market. These companies are stepping into the conversion of fixed capital expenditures into variable expenses by outsourcing to CDMOs, which enable them to handle spending more flexibly. Currently, CDMOs are utilising AI-enabled discovery, emerging new virus platforms, such as vesicular stomatitis virus (VSV) and arenaviruses, and highlighting manufacturing limitations.
On the other hand, the biotechnology companies segment is anticipated to grow rapidly. Ongoing breakthroughs in genetic engineering, viral platform development, and manufacturing techniques are encouraging oncolytic viruses as more viable and scalable. In the last few days, KaliVir Immunotherapeutics' vaccinia virus platform and Oncolytics Biotech's pelareorep have shown robustness in clinical trials by boosting immune responses in hard-to-treat cancers.
Browse More Insights of Towards Healthcare:
The CDMO Aseptic Filling Solutions Market is experiencing robust growth and is expected to continue booming throughout the forecast period, driven by rising demand for sterile manufacturing and specialized injectable therapies.
The CDMO services for pharma and biotech market is experiencing substantial growth from 2024 to 2034, driven by increasing outsourcing trends among pharmaceutical and biotech companies.
The active pharmaceutical ingredients CDMO market size is calculated at USD 127.45 billion in 2024, grew to USD 136.92 billion in 2025, and is projected to reach around USD 260.98 billion by 2034. The market is expanding at a CAGR of 7.43% between 2025 and 2034.
The global AAV vector CDMO services market size is calculated at USD 1.24 billion in 2024, grew to USD 1.43 billion in 2025, and is projected to reach around USD 5.14 billion by 2034. The market is expanding at a CAGR of 15.24% between 2025 and 2034.
The global small molecule CDMO market size is calculated at US$ 72.81 in 2024, grew to US$ 78.01 billion in 2025, and is projected to reach around US$ 145.12 billion by 2034. The market is expanding at a CAGR of 7.14% between 2025 and 2034.
The U.S. pharmaceutical CDMO market size is calculated at USD 36.77 billion in 2024, grew to USD 39.14 billion in 2025, and is projected to reach around USD 68.57 billion by 2034. The market is expanding at a CAGR of 6.43% between 2025 and 2034.
The global biotechnology CMO and CDMO market size is estimated at US$ 67.25 billion in 2024, is projected to grow to US$ 74.01 billion in 2025, and is expected to reach around US$ 199.67 billion by 2034. The market is projected to expand at a CAGR of 11.54% between 2025 and 2034.
The medical device CMO and CDMO market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2025 to 2034.
The Europe pharmaceutical CDMO market size is calculated at USD 35.48 billion in 2024, grew to USD 37.98 billion in 2025, and is projected to reach around USD 70.05 billion by 2034. The market is expanding at a CAGR of 7.04% between 2025 and 2034.
The oncolytic virus CDMO services market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2025 to 2034.
Recent Developments in the Oncolytic Virus CDMO Services Market
- In November 2025, KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company, made a clinical trial collaboration and supply agreement with Roche to study VET3-TGI, a new colytic immunotherapy.
- In May 2025, Tilt Biotherapeutics raised €22.6 million ($25.6 million) in a series B to unveil its experimental oncolytic adenovirus therapy in a Phase II trial for platinum-resistant ovarian cancer (PROC).
Oncolytic Virus CDMO Services Market Key Players List
- Catalent Inc.
- Lonza Group
- WuXi AppTec
- Brammer Bio (Thermo Fisher)
- Curia (formerly AMRI)
- Cobra Biologics
- Vigene Biosciences
- Oxford Biomedica
- REGENXBIO
- Oncolytics Biotech
- Viralgen Vector Core
- Avidity Biosciences
- GenScript Biotech
- Fujifilm Diosynth Biotechnologies
- Asymchem
- Sarepta Therapeutics
- MeiraGTx
- BioVectra
- AGC Biologics
- CleanCap Technologies
Segments Covered in the Report
By Service Type
- Upstream Manufacturing
- Virus Strain Development
- Cell Line Development
- Virus Amplification & Production
- Downstream Manufacturing
- Purification & Concentration
- Formulation & Fill-Finish
- Analytical & Quality Control Services
- Potency & Titer Testing
- Impurity Testing
- Sterility & Safety Testing
- Others
By Virus Type
- Adenovirus
- Herpes Simplex Virus (HSV)
- Reovirus
- Vaccinia Virus
- Others
By Therapeutic Area
- Melanoma
- Glioblastoma
- Solid Tumors
- Other Cancers
By End-User
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
By Region
- North America
- U.S.
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/6341
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
